Joi Lee1, Chi Chu1, David Guzman2, Valy Fontil2,3, Alexandra Velasquez1, Neil R Powe2,3, Delphine S Tuot4,5. 1. UCSF, Division of Nephrology at Zuckerberg San Francisco General Hospital, San Francisco, California, USA. 2. UCSF Division of General Internal Medicine at Zuckerberg San Francisco General Hospital, San Francisco, California, USA. 3. Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital, San Francisco, California, USA. 4. UCSF, Division of Nephrology at Zuckerberg San Francisco General Hospital, San Francisco, California, USA, delphine.tuot@ucsf.edu. 5. Center for Vulnerable Populations, Zuckerberg San Francisco General Hospital, San Francisco, California, USA, delphine.tuot@ucsf.edu.
Abstract
BACKGROUND: Detection of chronic kidney disease (CKD) with urine albumin-to-creatinine ratio (UACR) among patients with hypertension (HTN) provides an opportunity for early treatment, potentially mitigating risk of CKD progression and cardiovascular complications. Differences in UACR testing patterns among racial/ethnic populations at risk for CKD could contribute to known disparities in CKD complications. METHODS: We examined the prevalence of UACR testing among low-income adult primary care patients with HTN, defined by a new administrative code for HTN or 2 clinic blood pressures >140/90 mm Hg between January 1, 2014, and January 1, 2017, in one public health-care delivery system with a high prevalence of end-stage kidney disease among race/ethnic minorities. Logistic regression was used to identify odds of UACR testing within 1 year of a HTN diagnosis, overall, and by racial/ethnic subgroup, adjusted for demographic factors, estimated glomerular filtration rate, and HTN severity. Models were also stratified by diabetes status. RESULTS: The cohort (n = 16,414) was racially/ethnically diverse (16% White, 21% Black, 34% Asian, 19% Hispanic, and 10% other) and 51% female. Only 35% of patients had UACR testing within 1 year of a HTN diagnosis. Among individuals without diabetes, odds of UACR testing were higher among Asians, Blacks, and Other subgroups compared to Whites (adjusted OR [aOR] 1.19; 95% CI 1.00-1.42 for Blacks; aOR 1.33; 1.13-1.56 for Asians; aOR 1.30; 1.04-1.60 for Other) but were not significantly different between Hispanics and Whites (aOR 1.17; 0.97-1.39). Among individuals with diabetes, only Asians had higher odds of UACR testing compared to Whites (aOR 1.35; 1.12-1.63). CONCLUSIONS: Prevalence of UACR testing among low-income patients with HTN is low in one public health-care delivery system, with higher odds of UACR testing among racial/ethnic minority subgroups compared to Whites without diabetes and similar odds among those with diabetes. If generalizable, less albuminuria testing may not explain higher prevalence of kidney failure in racial/ethnic minorities.
BACKGROUND: Detection of chronic kidney disease (CKD) with urine albumin-to-creatinine ratio (UACR) among patients with hypertension (HTN) provides an opportunity for early treatment, potentially mitigating risk of CKD progression and cardiovascular complications. Differences in UACR testing patterns among racial/ethnic populations at risk for CKD could contribute to known disparities in CKD complications. METHODS: We examined the prevalence of UACR testing among low-income adult primary care patients with HTN, defined by a new administrative code for HTN or 2 clinic blood pressures >140/90 mm Hg between January 1, 2014, and January 1, 2017, in one public health-care delivery system with a high prevalence of end-stage kidney disease among race/ethnic minorities. Logistic regression was used to identify odds of UACR testing within 1 year of a HTN diagnosis, overall, and by racial/ethnic subgroup, adjusted for demographic factors, estimated glomerular filtration rate, and HTN severity. Models were also stratified by diabetes status. RESULTS: The cohort (n = 16,414) was racially/ethnically diverse (16% White, 21% Black, 34% Asian, 19% Hispanic, and 10% other) and 51% female. Only 35% of patients had UACR testing within 1 year of a HTN diagnosis. Among individuals without diabetes, odds of UACR testing were higher among Asians, Blacks, and Other subgroups compared to Whites (adjusted OR [aOR] 1.19; 95% CI 1.00-1.42 for Blacks; aOR 1.33; 1.13-1.56 for Asians; aOR 1.30; 1.04-1.60 for Other) but were not significantly different between Hispanics and Whites (aOR 1.17; 0.97-1.39). Among individuals with diabetes, only Asians had higher odds of UACR testing compared to Whites (aOR 1.35; 1.12-1.63). CONCLUSIONS: Prevalence of UACR testing among low-income patients with HTN is low in one public health-care delivery system, with higher odds of UACR testing among racial/ethnic minority subgroups compared to Whites without diabetes and similar odds among those with diabetes. If generalizable, less albuminuria testing may not explain higher prevalence of kidney failure in racial/ethnic minorities.
Authors: David M Eddy; L Gregory Pawlson; David Schaaf; Barbara Peskin; Andrei Shcheprov; Julia Dziuba; Jill Bowman; Benjamin Eng Journal: Health Aff (Millwood) Date: 2008 Sep-Oct Impact factor: 6.301
Authors: Allen R Nissenson; Allan J Collins; Judith Hurley; Hans Petersen; Brian J G Pereira; Earl P Steinberg Journal: J Am Soc Nephrol Date: 2001-08 Impact factor: 10.121
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: L Ebony Boulware; Bernard G Jaar; Michelle E Tarver-Carr; Frederick L Brancati; Neil R Powe Journal: JAMA Date: 2003-12-17 Impact factor: 56.272
Authors: Chi D Chu; Michael H Chen; Charles E McCulloch; Neil R Powe; Michelle M Estrella; Michael G Shlipak; Delphine S Tuot Journal: Kidney Med Date: 2021-06-01
Authors: Delphine S Tuot; Susan T Crowley; Lois A Katz; Joseph Leung; Delly K Alcantara-Cadillo; Christopher Ruser; Elizabeth Talbot-Montgomery; Joseph A Vassalotti Journal: JMIR Form Res Date: 2022-09-28
Authors: Chi D Chu; Neil R Powe; Charles E McCulloch; Tanushree Banerjee; Deidra C Crews; Rajiv Saran; Jennifer Bragg-Gresham; Hal Morgenstern; Meda E Pavkov; Sharon H Saydah; Delphine S Tuot Journal: Hypertension Date: 2020-11-16 Impact factor: 10.190
Authors: Nikita Stempniewicz; Joseph A Vassalotti; John K Cuddeback; Elizabeth Ciemins; Amy Storfer-Isser; Yingying Sang; Kunihiro Matsushita; Shoshana H Ballew; Alex R Chang; Andrew S Levey; Robert A Bailey; Jesse Fishman; Josef Coresh Journal: Diabetes Care Date: 2021-07-07 Impact factor: 17.152
Authors: Chi D Chu; Neil R Powe; Charles E McCulloch; Deidra C Crews; Yun Han; Jennifer L Bragg-Gresham; Rajiv Saran; Alain Koyama; Nilka R Burrows; Delphine S Tuot Journal: JAMA Netw Open Date: 2021-09-01